Document Detail


Defining patients at high risk for gastrointestinal hemorrhage after drug-eluting stent placement: a cost utility analysis.
MedLine Citation:
PMID:  20236217     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The study goal was to evaluate the cost-effectiveness of drug-eluting stent (DES) placement with consideration of gastrointestinal (GI) bleeding risk. DES reduce the need for future coronary revascularization, but require prolonged dual anti-platelet (DAT) therapy, which may increase the risk for GI bleeding. While DES have been found to be cost-effective in patients at average risk for GI bleeding, they may not be the most cost-effective strategy in higher risk patients. METHODS: A Markov model was created to compare DES with bare metal stents (BMS). Patients were a hypothetical cohort of 60-year-old individuals with coronary artery stenosis that required nonemergent percutaneous coronary revascularization (PCI). The primary outcomes were the threshold incremental risks of GI bleeding from DAT based on willingness to pay (WTP) of $50,000, $100,000, and $150,000 per quality adjusted life year (QALY) gained. RESULTS: For a WTP of $100,000, the relative risk of GI bleeding from DAT could be as high as 10.8 (when compared to aspirin alone) before DES would no longer be cost-effective. In patients with two risk factors for GI bleeding, the threshold relative risk could be as low as 1.6. CONCLUSION: In average-risk patients, the risk of GI bleeding from DAT can be substantial without affecting the cost-effectiveness of DES. However, DES are unlikely to be cost-effective in patients with two or more risk factors for GI bleeding.
Authors:
Neil Gupta; Rahul Nayak; Scott W Grisolano; Daniel C Buckles; Peter N Tadros
Related Documents :
21621477 - Prevention of venous thromboembolism in long-term care: results of a multicenter educat...
9807287 - Risk-assessment scores, prevention strategies, and the incidence of pressure ulcers amo...
2210467 - Towards a true prevalence of peptic ulcer: the sørreisa gastrointestinal disorder study.
21654437 - Reduction in personnel and long-term sickness absence for psychiatric disorders among e...
15243287 - Preventing clinically evident coronary heart disease in the postmenopausal woman.
18697887 - Impact of risk information on perceived colorectal cancer risk: a randomized trial.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-03-02
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  23     ISSN:  1540-8183     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-05-14     Completed Date:  2010-08-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  179-87     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology/Hepatology, University of Kansas Medical Center, Kansas City, KS 66160, USA. ngupta@kumc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary
Aspirin / therapeutic use
Cohort Studies
Coronary Stenosis / therapy*
Cost-Benefit Analysis
Drug-Eluting Stents / adverse effects*,  economics*
Equipment Design
Gastrointestinal Hemorrhage / etiology*
Humans
Markov Chains
Middle Aged
Patients*
Quality-Adjusted Life Years
Risk
Risk Assessment
Stents / adverse effects
Chemical
Reg. No./Substance:
50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferat...
Next Document:  Congenital digital aplasia in a free-ranging group of silvery marmosets, Mico argentatus.